Definium Therapeutics (DFTX) Other Accumulated Expenses (2019 - 2026)
Definium Therapeutics (DFTX) reported Other Accumulated Expenses of $604000.0 for Q1 2026, up 131.42% year-over-year from $261000.0 in Q1 2025, and up 18.43% on a QoQ basis from $510000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Other Accumulated Expenses data on file, last reported at $604000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 131.42% year-over-year to $604000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $604000.0 (up 131.42% YoY) and the FY2025 annual result came in at $510000.0, up 83.45% from the prior year.
- Other Accumulated Expenses advanced to $604000.0 in Q1 2026 per DFTX's latest filing, from $510000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $685000.0 in Q2 2024 and bottomed at $45000.0 in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $291000.0 (2024), against an average of $312764.7.
- Peak annual rise in Other Accumulated Expenses reached 2300.0% in 2022, while the deepest fall reached 92.29% in 2022.
- Tracing DFTX's Other Accumulated Expenses over 5 years: stood at $72000.0 in 2022, then soared by 401.39% to $361000.0 in 2023, then declined by 22.99% to $278000.0 in 2024, then soared by 83.45% to $510000.0 in 2025, then grew by 18.43% to $604000.0 in 2026.
- Per Business Quant, the three latest DFTX Other Accumulated Expenses figures stand at $604000.0 (Q1 2026), $510000.0 (Q4 2025), and $498000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 261,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 685,000.00 |
| Mar 31, 2024 | 291,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | 436,000.00 |
| Jun 30, 2023 | 90,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 228,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Jun 30, 2021 | 1.32 Mn |
| Mar 31, 2021 | 584,000.00 |
| Dec 31, 2020 | 186,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 213,000.00 |
| Mar 31, 2020 | 365,000.00 |
| Dec 31, 2019 | 385,000.00 |